GlassScriptPhysician profile
Carlos A Ramos
NPI 1619162906
$2,234.90
in general payments reported to CMS, 2019-2025
24 companies · $55.18 in 2025
The $55.18 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $159 · 2021: $786 · 2022: $23.42 · 2023: $221 · 2025: $55.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $650.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $332.86 | 2019-2023 | Kymriah |
| Amgen INC. | $197.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $128.61 | 2019-2020 | |
| Astellas Pharma US INC | $120.69 | 2019 | |
| Celgene Corporation | $99.73 | 2019-2025 | Breyanzi |
| Janssen Biotech, INC. | $89.15 | 2021 | |
| Incyte Corporation | $73.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.83 | 2019 | |
| Servier Pharmaceuticals LLC | $49.53 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $49.07 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.42 | 2019 | |
| Dova Pharmaceuticals | $42.04 | 2019 | |
| Amag Pharmaceuticals, INC. | $39.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.30 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $34.16 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $32.98 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $32.28 | 2019 | |
| Kite Pharma, INC. | $30.29 | 2025 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $24.49 | 2019 | |
| Genzyme Corporation | $24.42 | 2019 | |
| Coherus Oncology, INC. | $21.52 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.65 | 2019 | |
| Array Biopharma INC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.